DOCSLIB.ORG

Chenodeoxycholic Acid Plus Cholic Acid Gut: First Published As 10.1136/Gut.38.4.623 on 1 April 1996

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chenodeoxycholic Acid Plus Cholic Acid Gut: First Published As 10.1136/Gut.38.4.623 on 1 April 1996 Gut 1996; 38: 623-628 623 A4-3-Oxosteroid 51-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid Gut: first published as 10.1136/gut.38.4.623 on 1 April 1996. Downloaded from P T Clayton, K A Mills, A W Johnson, A Barabino, M G Marazzi Abstract mass spectrometry (FAB-MS) or liquid sec- Background-In some infants with liver ondary ion mass spectrometry (LSI-MS). disease, 3-oxo-A4 bile acids are the major These techniques can be used to analyse the bile acids in urine, a phenomenon cholanoids (bile acids and bile alcohols) in a attributed to reduced activity of the A4-3- urine sample.2-6 Most children with cholesta- oxosteroid 5p-reductase required for syn- tic liver disease excrete increased amounts of thesis ofchenodeoxycholic acid and cholic normal bile acids (principally the taurine and acid. These patients form a heterogeneous glycine conjugates of cholic acid and chen- group. Many have a known cause of odeoxycholic acid) but in a few, one of four hepatic dysfunction and plasma concen- unusual patterns of cholanoid excretion can trations of chenodeoxycholic acid and be recognised.6 One of these is characterised cholic acid that are actually greater than by the presence of ions attributable to the those of the 3-oxo-A4 bile acids. It is glycine and taurine conjugates of 7ot- unlikely that these patients have a hydroxy-3-oxo-4-cholenoic acid and 7oa,122o- primary genetic deficiency of the 51- dihydroxy-3-oxo-4-cholenoic acid.5-10 It is reductase enzyme. generally accepted that this pattern arises as a Aims-To document the bile acid profile, result of reduced activity of the enzyme clinical phenotype, and response to treat- that converts 7ot-hydroxy-cholest-4-en-3-one ment of an infant with cholestasis, to 7ot-hydroxy-5,B-cholestan-3-one and 7a., increased plasma concentrations of 3- 1 2a-dihydroxy-cholest-4-en-3-one to 7, 1 2aL- oxo-A4 bile acids, low plasma concentra- hydroxy-5,B-cholestan-3-one (Fig 1). As a tions of chenodeoxycholic acid and cholic result of the &4-3-oxosteroid 5 -reductase http://gut.bmj.com/ acid, and no other identifiable cause of deficiency, 3-oxo-A4 intermediates undergo liver disease. side chain oxidation to produce the corres- Patients-This infant was compared with ponding 3-oxo-A4 bile acids, which are con- normal infants and infants with cholesta- jugated with glycine and taurine but cannot sis ofknown cause. be secreted into the bile and appear in the Methods-Analysis of bile acids by liquid urine.6 The activity of A4-3-oxosteroid 5ot- secondary ionisation mass spectrometry reductase is preserved, leading to the appear- on September 30, 2021 by guest. Protected copyright. and gas chromatography - mass spec- ance of increased amounts of 5ot [H] -or trometry, allo-bile acids in plasma. The difficulty Results-The plasma bile acid profile of in an individual patient is deciding whether the patient was unique. She had chronic the 51-reductase deficiency is the primary cholestatic liver disease associated with cause of the liver disease or whether malabsorption of vitamins D and E and a reduced activity of the enzyme is a conse- normal y-glutamyltranspeptidase when quence of hepatocyte damage. This has also the transaminases were increased. The made it difficult to define the phenotype, liver disease failed to improve with natural history, and response to treatment ursodeoxycholic acid but responded to a of primary A4-3-oxosteroid 5,B-reductase combination of chenodeoxycholic acid deficiency. Institute of Child and cholic acid. Patients with deficiency have Health and Great 5p-reductase Ormond Street Conclusion-Treatment of primary 513- been treated with various combinations of Hospital for Children, reductase deficiency requires the use of bile acids."1 There is little information on the London bile acids that inhibit cholesterol 7a- use of ursodeoxycholic acid alone. This is P T Clayton K A Mills hydroxylase. important because this is the bile acid that A W Johnson (Gut 1996; 38: 623-628) is most widely used in the treatment of cholestatic disorders of childhood. In this Istituto G Gaslini, Keywords: inborn error, bile acid synthesis, giant cell paper we present a child with chronic Universita di Genova, hepatitis, cholestasis. Italy cholestatic liver disease who failed to respond A Barabino to ursodeoxycholic acid treatment but M G Marazzi improved rapidly with a combination of Correspondence to: Diagnosis of inborn errors of bile acid synthe- chenodeoxycholic acid and cholic acid. The Dr P T Clayton, Division of Biochemistry and Genetics, sis is important because specific treatment is low concentrations of primary bile acids in Institute of Child Health, 30 available in the form of oral supplements of the patient's plasma, urine, and duodenal Guilford Street, London bile acids and such treatment is often dra- juice before treatment suggested that this WC1N 1EH. 2 Accepted for publication matically effective.1 Rapid diagnosis is made patient probably had primary A4-3-oxosteroid 31 October 1995 possible by the use of fast atom bombardment 5,B-reductase deficiency. 624 Clayton, Mills, J7ohnson, Barabino, Marazzi (OH) (OH) cholestasis with steatorrhoea, failure to thrive, Sidechain oxidation - COOH and clinical rickets. At the age of 3 months, COOH investigations in the Gaslini Institute of Genoa showed a normal serumalantitrypsin concen- tration, red cell galactose-l-phosphate uridyl Gut: first published as 10.1136/gut.38.4.623 on 1 April 1996. Downloaded from "'OH I J,,,J "OH transferase, and UDP-galactose-4-epimerase. bile acids .ductase 5a-Reductase 3-oxo-A4 Plasma tyrosine was pu (normal Sidechain oxidation 40-130), plasma threonine 450F M (normal (OH) (OH) 65-185), and plasma methionine 10pu M 15-31). The urine organic acid analy- COOH sis(normalshowed increased excretion of 4-hydrox- yphenyl-pyruvic and -lactic acids but no a H ,H succinyl acetone. Plasma analysis showed "'OH HO H H low vitamin E concentration (1.4,u M; normal Allo-chenodeoxycholi acid 11.5-35) but a normal vitamin A concentra- allo-cholic acid tion. Serum ferritin was increased. Ultrasound (OH) A11°acand bladder and no dilatation J-(OH) showed a normal gall COOH of extrahepatic bile ducts. A liver biopsy at 4 1 1 months showed lobular disarray resulting from Chenodeoxycholic acid extensive giant cell transformation and H "OH'CheOHand cholic acid Thenecroticportalfocispaceswith granulocytewere of normalaccumulation.size and Figure 1: The effect of reduced activityof A4-3-oxosteroid5,8-reductase: reduced synthesis shape and the interlobular bile duct could of conjugcates of chenodeoxycholic acid and cholic acid and increased synthesis of (a) conjugate. of 7a-hydroxy-3-oxo-4-cholenoic acid and 7a,12a-dihydroxy-4-cholenoic acid, always be visualised. Some portal tracts were (b) allo-c:henodeoxycholic acid and allo-cholic acid. infiltrated by lymphocytes and some bile duct epithelial cells were vacuolated. The paren- Case report chyma showed considerable macrovesicular Our patient was the second child of unrelated steatosis and bile pigment accumulation. Sardinian parents. Her mother took carba- Granules of haemosiderin were localised mazepine throughout the pregnancy. The almost exclusively to Kupffer cells. infant was born at 37 weeks gestation and was Between the ages of 3 and 8 months our breast fed. She developed mild jaundice but patient had persistent jaundice with failure to remained well until the third week of life when thrive and steatorrhoea when fed a normal she developed fever, pronounced jaundice, and formula. She continued to fail to thrive when drowsiness. Investigations showed: bilirubin fed with Pregestemil, partly because of poor http://gut.bmj.com/ 316,uM (conjugated 145,uM), aspartate intake. Treatment with ursodeoxycholic acid aminotransferase (AST) 2279 IU/1 (normal at a dose of 12 mgfkg/d and then at a dose of 20-60), alanine aminotransferase (ALT) 1123 20 mgfkg/d did not lead to any clinical IU/1 (normal 5-45), y-glutamyltranspeptidase improvement or to significant improvement in (y-GT) 102IU/1 (normal 5-51), prothrombin liver function tests (Fig 2). The alkaline phos- time 15.4 seconds (control 12 seconds),ox feto- phatase fell in response to parenteral vitamin protein 680 000 ,ug/l. Screening tests for D. Vitamins A, E, and K were also given on September 30, 2021 by guest. Protected copyright. hepatitis viruses were negative. The plasma parenterally. The urine bile acids were first carbamazepine concentration was 1.4,ug/l and analysed when the patient was 0.3 years, the consequently breast feeding was stopped. The ursodeoxycholic acid treatment having been patient's liver function tests showed some stopped for two weeks. improvement but there was persistent At the age of 0.69 years the patient was seen at Great Ormond Street. She had been receiv- Chenodeoxycholic ing ursodeoxycholic acid treatment at a dose of Cholic 20 mglkg/d for 0.4 years. Examination showed a weight well below the third percentile, length Ursodec just below the third percentile, and head cir- )xycholic cumference just below the second percentile. - She was wasted and jaundiced but there were s0 no stigmata of chronic liver disease. The liver was cm from the costal ii )o _ \edge palpable 5-5 margin in the mid-clavicular line and 5 cm so- \ from the xiphisternum in the midline. m Investigations showed: haemoglobin 96 g/l 0 with normallindices, ferritin 245 gg/l (normal 100 0o 7-150), serum iron 13.7 jiM (normal 14-22), - 80)o A total iron binding capacity 54-9 ,uM (normal 60)o _ _ \42-66), copper 17.3 ,uM (normal 12.6-26.8), 1- 40 73-210).
Load more

Recommended publications
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • |||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka Et Al
    |||||||||||||III US005202354A United States Patent (19) (11) Patent Number: 5,202,354 Matsuoka et al. 45) Date of Patent: Apr. 13, 1993 (54) COMPOSITION AND METHOD FOR 4,528,295 7/1985 Tabakoff .......... ... 514/562 X REDUCING ACETALDEHYDE TOXCTY 4,593,020 6/1986 Guinot ................................ 514/811 (75) Inventors: Masayoshi Matsuoka, Habikino; Go OTHER PUBLICATIONS Kito, Yao, both of Japan Sprince et al., Agents and Actions, vol. 5/2 (1975), pp. 73) Assignee: Takeda Chemical Industries, Ltd., 164-173. Osaka, Japan Primary Examiner-Arthur C. Prescott (21) Appl. No.: 839,265 Attorney, Agent, or Firn-Wenderoth, Lind & Ponack 22) Filed: Feb. 21, 1992 (57) ABSTRACT A novel composition and method are disclosed for re Related U.S. Application Data ducing acetaldehyde toxicity, especially for preventing (63) Continuation of Ser. No. 13,443, Feb. 10, 1987, aban and relieving hangover symptoms in humans. The com doned. position comprises (a) a compound of the formula: (30) Foreign Application Priority Data Feb. 18, 1986 JP Japan .................................. 61-34494 51) Int: C.5 ..................... A01N 37/00; A01N 43/08 52 U.S. C. ................................. ... 514/562; 514/474; 514/81 wherein R is hydrogen or an acyl group; R' is thiol or 58) Field of Search ................ 514/557, 562, 474,811 sulfonic group; and n is an integer of 1 or 2, (b) ascorbic (56) References Cited acid or a salt thereof and (c) a disulfide type thiamine derivative or a salt thereof. The composition is orally U.S. PATENT DOCUMENTS administered, preferably in the form of tablets. 2,283,817 5/1942 Martin et al.
    [Show full text]
  • Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes
    Article AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5′-Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes Ju-Hyun Kim 1, Soon-Sang Kwon 1, Tae Yeon Kong 1, Jae Chul Cheong 2, Hee Seung Kim 2, Moon Kyo In 2 and Hye Suk Lee 1,* 1 Drug Metabolism and Bioanalysis Laboratory, College of Pharmacy, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon 14662, Korea; [email protected] (J.-H.K.); [email protected] (S.-S.K.); [email protected] (T.Y.K.) 2 Forensic Chemistry Laboratory, Forensic Science Division, Supreme Prosecutor’s Office, 157 Banpo-daero, Seocho-gu, Seoul 06590, Korea; [email protected] (J.C.C.); [email protected] (H.S.K.); [email protected] (M.K.I.) * Correspondence: [email protected]; Tel.: +82-2-2164-4061 Academic Editor: Diego Muñoz-Torrero Received: 22 February 2017; Accepted: 8 March 2017; Published: date Abstract: AM-2201 is a synthetic cannabinoid that acts as a potent agonist at cannabinoid receptors and its abuse has increased. However, there are no reports of the inhibitory effect of AM-2201 on human cytochrome P450 (CYP) or uridine 5′-diphospho-glucuronosyltransferase (UGT) enzymes. We evaluated the inhibitory effect of AM-2201 on the activities of eight major human CYPs (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) and six major human UGTs (1A1, 1A3, 1A4, 1A6, 1A9, and 2B7) enzymes in pooled human liver microsomes using liquid chromatography–tandem mass spectrometry to investigate drug interaction potentials of AM-2201. AM-2201 potently inhibited CYP2C9-catalyzed diclofenac 4′-hydroxylation, CYP3A4-catalyzed midazolam 1′-hydroxylation, UGT1A3-catalyzed chenodeoxycholic acid 24-acyl-glucuronidation, and UGT2B7-catalyzed naloxone 3-glucuronidation with IC50 values of 3.9, 4.0, 4.3, and 10.0 µM, respectively, and showed mechanism-based inhibition of CYP2C8-catalyzed amodiaquine N-deethylation with a Ki value of 2.1 µM.
    [Show full text]
  • OCALIVA™ (Obeticholic Acid) Oral
    PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 9/15/2016 SECTION: DRUGS LAST REVIEW DATE: 8/19/2021 LAST CRITERIA REVISION DATE: 8/19/2021 ARCHIVE DATE: OCALIVA™ (obeticholic acid) oral Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines. The section identified as “Description” defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as “Criteria” defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Pharmacy Coverage Guidelines are subject to change as new information becomes available. For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable. BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans.
    [Show full text]
  • Ocaliva (Obeticholic Acid)
    HIGHLIGHTS OF PRESCRIBING INFORMATION Staging/ Classification Non-Cirrhotic or Child-Pugh Class B These highlights do not include all the information needed to use Compensated Child- or C or Patients OCALIVA® safely and effectively. See full prescribing information for Pugh Class A with a Prior OCALIVA. Decompensation a Event ® OCALIVA (obeticholic acid) tablets, for oral use Starting OCALIVA 5 mg once daily 5 mg once weekly Initial U.S. Approval: 2016 Dosage for first 3 months WARNING: HEPATIC DECOMPENSATION AND FAILURE IN OCALIVA Dosage 10 mg once daily 5 mg twice weekly INCORRECTLY DOSED PBC PATIENTS WITH CHILD-PUGH Titration after first (at least 3 days apart) CLASS B OR C OR DECOMPENSATED CIRRHOSIS 3 months, for patients See full prescribing information for complete boxed warning who have not achieved Titrate to 10 mg an adequate reduction twice weekly (at least • In postmarketing reports, hepatic decompensation and failure, in in ALP and/or total 3 days apart) based bilirubin and who are on response and some cases fatal, have been reported in patients with primary biliary b tolerating OCALIVA tolerability cholangitis (PBC) with decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when OCALIVA was dosed more Maximum OCALIVA 10 mg once daily 10 mg twice weekly frequently than recommended. (5.1) Dosage (at least 3 days apart) a • The recommended starting dosage of OCALIVA is 5 mg once weekly Gastroesophageal variceal bleeding, new or worsening jaundice, for patients with Child-Pugh Class B or C hepatic impairment or a spontaneous bacterial peritonitis, etc. b prior decompensation event.
    [Show full text]
  • Biliary Bile Acid Composition of the Human Fetus in Early Gestation
    0031-3998/87/2102-0197$02.00/0 PEDIATRIC RESEARCH Vol. 21, No.2, 1987 Copyright© 1987 International Pediatric Research Foundation, Inc. Printed in U.S.A. Biliary Bile Acid Composition of the Human Fetus in Early Gestation C. COLOMBO, G. ZULIANI, M. RONCHI, J. BREIDENSTEIN, AND K. D. R. SETCHELL Department q/Pediatrics and Obstetrics, University q/ Milan, Milan, Italy [C. C., G.Z., M.R.j and Department q/ Pediatric Gastroel1/erology and Nwrition, Children's Hospital Medical Center, Cincinnati, Ohio 45229 [J.B., K.D.R.S.j ABSTRACf. Using analytical techniques, which included the key processes of the enterohepatic circulation of bile acids capillary column gas-liquid chromatography and mass ( 16-19). As a result of physiologic cholestasis, the newborn infant spectrometry, detailed bile acid profiles were obtained for has a tendency to develop a true neonatal cholestasis when 24 fetal bile samples collected after legal abortions were subjected to such stresses as sepsis, hypoxia, and total parenteral performed between the 14th and 20th wk of gestation. nutrition ( 15). Qualitatively, the bile acid profiles of all fetal bile samples Abnormalities in bile acid metabolism have been suggested to were similar. The predominant bile acids identified were be a factor in the development of certain forms of cholestasis in chenodeoxycholic and cholic acid. The presence of small the newborn (20) and in animal models the hepatotoxic nature but variable amounts of deoxycholic acid and traces of of bile acids has been well established (21-24). A greater under­ lithocholic acid suggested placental transfer of these bile standing of the etiology of these conditions requires a better acids from the maternal circulation.
    [Show full text]
  • Cholic Acid for Treating Inborn Errors of Primary Bile Acid Synthesis NHS England Unique Reference Number URN1623 / NICE ID004
    NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Clinical evidence review of cholic acid for treating inborn errors of primary bile acid synthesis NHS England unique reference number URN1623 / NICE ID004 Prepared by: NICE on behalf of NHS England Specialised Commissioning About this clinical evidence review Clinical evidence reviews are a summary of the best available evidence for a single technology within a licensed indication, for commissioning by NHS England. The clinical evidence review supports NHS England in producing clinical policies but is not NICE guidance or advice. Summary This evidence review considers cholic acid (Laboratoires CTRS [Orphacol] and Retrophin Europe Ltd [Kolbam]) for treating inborn errors of primary bile acid NICE clinical evidence review of cholic acid for treating inborn errors of primary bile acid synthesis Page 1 of 72 NHS URN1623 NICE ID004 synthesis caused by the following enzyme deficiencies in people aged 1 month and over: 3-beta-hydroxy-delta5-C27-steroid oxidoreductase (3beta-HSD) delta4-3-oxosteroid-5-beta reductase (5beta-reductase) 2- (or alpha-) methylacyl-CoA racemase (AMACR) sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis [CTX]) cholesterol 7alpha-hydroxylase (CYP7A1). Inborn errors of primary bile acid synthesis are rare genetic conditions in which enzyme deficiencies prevent the liver from converting cholesterol in the body to bile acids (such as cholic acid and chenodeoxycholic acid). This results in the liver producing high concentrations of atypical (or ‘unusual’) bile acids and intermediary metabolites (some of which are toxic to the liver) in an attempt to establish a normal bile acid pool. Accumulation of potentially toxic atypical bile acids and metabolites, and reduced flow of bile acids may cause liver injury.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • TRANSPARENCY COMMITTEE Opinion 19 February 2014
    The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 February 2014 ORPHACOL 50 mg, hard capsule B/30 (CIP 34009 416 886 0 7) B/60 (CIP 34009 416 887 7 5) ORPHACOL 250 mg, hard capsule B/30 (CIP: 34009 416 890 8 6) Applicant: CTRS INN cholic acid ATC Code (2012) A05AA03 (Bile acid preparations) Reason for the Inclusion request List concerned Hospital use (French Public Health Code L.5123-2) "Treatment of inborn errors in primary bile acid synthesis due to 3β-hydroxy-∆5-C -steroid oxidoreductase deficiency or ∆4-3-oxosteroid- Indication concerned 27 5β-reductase deficiency in infants, children and adolescents aged 1 month to 18 years and adults." HAS - Medical, Economic and Public Health Assessment Division 1/20 Actual Benefit Substantial. The benefits of using cholic acid in the treatment of inborn errors in primary 5 bile acid synthesis due to 3 β-hydroxy-∆ -C27 -steroid oxidoreductase deficiency or ∆4-3-oxosteroid-5β-reductase deficiency as soon as they are diagnosed have been established since 1993, when the first hospital preparation was made available in France by the AP-HP [Paris public hospital system], followed by temporary authorisations for use by a named patient [ATU nominative in French] since 2007. In particular, none of the 20 patients followed in France and treated with cholic acid since this date have needed a liver transplant, the only other treatment option. Treatment Improvement in with cholic acid allows postponing liver transplantation and improving Actual Benefit overall symptomatology, normalising lab work results and improving histological liver lesions, with good safety.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]
  • Kolbam, INN-Cholic Acid
    24 September 2015 EMA/689761/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Kolbam Medicinal International non-proprietary name: cholic acid Procedure No. EMEA/H/C/002081/0000product Note no Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. longer authorised 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. Table of contents 1.1. Submission of the dossier ...................................................................................... 5 1.2. Manufacturers ...................................................................................................... 7 1.3. Steps taken for the assessment of the product ......................................................... 7 2. Scientific discussion ................................................................................ 9 2.1. Introduction......................................................................................................... 9 2.2. Quality aspects .................................................................................................. 11 2.2.1. Introduction .................................................................................................... 11 2.2.2. Active Substance ............................................................................................
    [Show full text]